

Biosimilars Policy Resources

General

- [Health Canada Fact Sheet: Biosimilars](#)
- Drug and Health Product Portal, Summary Basis of Decision: [Review Decisions](#)
- [CADTH: Biosimilar Drugs – Your Questions Answered](#)
- [International Coalition of Medicines Regulatory Authorities Biosimilars Statement \(PDF\)](#)
- [Biosimilars in the EU: Information Guide for Healthcare Professionals](#)
- [Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU](#)

Nocebo Effect

- [Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review](#)

Switching

- Biosimilars Canada: <https://biosimilarscanada.ca/resources/switching/>
- [Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis](#)
- [The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review](#)
- [The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence](#)

Arthritis

- [Arthritis Society Canada: Biologics and Biosimilars](#)
- [Joint Health: Facts About Biosimilar Biologics](#)

Inflammatory Bowel Disease

- [Canadian Digestive Health Foundation: Biosimilar Library](#)
- [Nonmedical switch of anti-TNF- \$\alpha\$ biosimilars has no major clinical, pharmacokinetic and psychological impact on patients with IBD - the SAFER Study](#)

Osteoporosis

- Osteoporosis Canada: [Biosimilars](#)
- Osteoporosis Canada: [Video: Biosimilar for Patients on Denosumab](#)
- Osteoporosis Canada: [Video: Biologics and Biosimilars – An Overview for Healthcare Providers](#)

Asthma/Allergy

- Asthma.ca: [Biologic Treatment for Asthma](#)

Denosumab

- [Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study](#)

Omalizumab

- [Efficacy and safety of CT-P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16-week follow-up study](#)
- [CT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, Active-Controlled, Phase 3 Study](#)

Tocilizumab

- [Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomized, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47](#)

Ustekinumab

- Jamteki™
[Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis](#)
- Otulfi®
[A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis](#)
- Wezlana™
[Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks](#)